SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$533M
Q3 2021
Positions
38
Filings on Record
31
2019–present window
Filed
Nov 15, 2021
original filing

Summary

Lion Point Capital, LP reported $533M in U.S.-listed holdings across 38 positions for Q3 2021.

Its largest position, Marinus Pharmaceuticals, represents 7.7% of the portfolio.

Compared with Q2 2021, the fund opened 6 new positions and exited 3.

Portfolio Metrics

Turnover
+10.2%
vs prior filed quarter
Top-10 Concentration
+51.4%
share of reported value
Largest Position
+7.7%
Marinus Pharmaceuticals
New / Exited
6 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 52.1%ETP: 24.6%Other: 22.6%US DOMESTIC: 0.6%
  • Common Stock · 52.1% · $278M
  • ETP · 24.6% · $131M
  • Other · 22.6% · $121M
  • US DOMESTIC · 0.6% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
OPHTEURIVERIC BIO INCNEW+706.2K706.2K+$11M$11M
RENEW ENERGY GLOBAL PLCNEW+1.00M1.00M+$10M$10M
ATRAGBXATARA BIOTHERAPEUTICS INCNEW+350.5K350.5K+$6M$6M
IQIYI INCNEW+4.00M4.00M+$3M$3M
IMARA INCNEW+833.3K833.3K+$3M$3M
MCRB1EURSERES THERAPEUTICS INCNEW+481.8K481.8K+$3M$3M
AAALCOA CORPADDED+200.0K201.0K+$10M$10M
CNPCENTERPOINT ENERGY INCSOLD OUT−975.0K0−$24M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

32 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MARINUS PHARMACEUTICALS INCCOM NEW7.74%$41M3.63M
2ARCONIC CORPORATIONCOM7.17%$38M1.21M
3LIBERTY GLOBAL PLCSHS CL A · SHS CL C7.12%$38M1.27M
4SWCHFSIERRA WIRELESS INChistory →COM6.23%$33M2.14M
5TGTXTG THERAPEUTICS INChistory →COM5.24%$28M839.1K
60LSBURGERFI INTERNATIONAL INChistory →COM4.46%$24M2.75M
7FEFIRSTENERGY CORPhistory →COM4.17%$22M625.0K
8DRRXEURDURECT CORPhistory →COM3.72%$20M15.49M
9EXTRACTION OIL & GAS INCCOM2.85%$15M269.6K
10COMPUTE HEALTH ACQUISITIN COUNIT 99/99/99992.80%$15M1.49M
11OPHTEURIVERIC BIO INChistory →COM2.15%$11M706.2K
12RENEW ENERGY GLOBAL PLCCL A SHS1.89%$10M1.00M
13CC NEUBERGER PRINCIPAL HOLDNUNIT 99/99/99991.87%$10M1.00M
14BATLBATTALION OIL CORPhistory →COM1.74%$9M953.9K
151T7TRICIDA INChistory →COM1.59%$8M1.83M
16JAWS MUSTANG ACQUISITION CORUNIT 99/99/99991.51%$8M800.0K
17ATRAGBXATARA BIOTHERAPEUTICS INChistory →COM1.18%$6M350.5K
18KINIKSA PHARMACEUTICALS LTDCOM CL A1.06%$6M495.7K
19FORTRESS VALUE ACQUISI CORPUNIT 03/31/20280.92%$5M500.0K
20LUMOS PHARMA INCCOM0.73%$4M407.2K
21IQIYI INCNOTE 4.000%12/10.64%$3M4.00M
22IMARA INCCOM0.64%$3M833.3K
23MCRB1EURSERES THERAPEUTICS INCCOM0.63%$3M481.8K
24AGLEUSDAEGLEA BIOTHERAPEUTICS INCCOM0.45%$2M300.0K
25INNOVIZ TECHNOLOGIES LTDSHS0.43%$2M400.0K
26LOGCUSDLOGICBIO THERAPEUTICS INCCOM0.43%$2M500.0K
27FORTRESS CAPITAL ACQUISITIONUNIT 99/99/99990.42%$2M230.7K
28NXTCEURNEXTCURE INCCOM0.38%$2M300.0K
29OUTFRONT MEDIA INCCOM0.35%$2M75.0K
30ORIGIN MATERIALS INCCOM0.13%$681,000100.0K
31AAALCOA CORPCOM0.01%$48,0001.0K
32SCOR1EURCOMSCORE INCCOM0.00%$3,0001.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.